;PMID: 9777951
;source_file_1394.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:40..185] = [t:40..185]
;2)section:[e:189..261] = [t:189..261]
;3)section:[e:265..407] = [t:265..407]
;4)sentence:[e:411..589] = [t:411..589]
;5)sentence:[e:590..734] = [t:590..734]
;6)sentence:[e:735..796] = [t:735..796]
;7)sentence:[e:797..889] = [t:797..889]
;8)sentence:[e:890..981] = [t:890..981]
;9)sentence:[e:982..1161] = [t:982..1161]
;10)sentence:[e:1162..1312] = [t:1162..1312]
;11)sentence:[e:1313..1394] = [t:1313..1394]
;12)sentence:[e:1395..1472] = [t:1395..1472]
;13)sentence:[e:1473..1540] = [t:1473..1540]
;14)sentence:[e:1541..1621] = [t:1541..1621]
;15)sentence:[e:1622..1774] = [t:1622..1774]
;16)sentence:[e:1775..1997] = [t:1775..1997]
;17)section:[e:2001..2045] = [t:2001..2045]

;section 0 Span:0..35
;Am J Pathol  1998 Oct;153(4):1201-9
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..11] Pathol) (CD:[13..17] 1998)
        (.:[18..26] Oct;153-LRB-) (CD:[26..28] 4-RRB-) (CD:[28..33] :1201)
        (HYPH:[33..34] -) (CD:[34..35] 9)))

;sentence 1 Span:40..185
;Specific K-ras2 mutations in human sporadic colorectal adenomas are
;associated  with DNA near-diploid aneuploidy and inhibition of
;proliferation.
;[49..55]:gene-rna:"K-ras2"
;[75..103]:malignancy:"sporadic colorectal adenomas"
;[125..152]:variation-type:"DNA near-diploid aneuploidy"
(SENT
  (S-HLN
    (NP-SBJ-1
      (NP (JJ:[40..48] Specific) (NN:[49..55] K-ras2) (NNS:[56..65] mutations))
      (PP-LOC (IN:[66..68] in)
        (NP (JJ:[69..74] human)
           (JJ:[75..83] sporadic) (JJ:[84..94] colorectal)
           (NNS:[95..103] adenomas))))
    (VP (VBP:[104..107] are)
      (VP (VBN:[108..118] associated)
        (NP-1 (-NONE-:[118..118] *))
        (PP-CLR (IN:[120..124] with)
          (NP
            (NP (NN:[125..128] DNA)
              (ADJP (JJ:[129..133] near) (HYPH:[133..134] -)
                    (JJ:[134..141] diploid))
              (NN:[142..152] aneuploidy))
            (CC:[153..156] and)
            (NP
              (NP (NN:[157..167] inhibition))
              (PP (IN:[168..170] of)
                (NP (NN:[171..184] proliferation))))))))
    (.:[184..185] .)))

;section 2 Span:189..261
;Giaretti W, Rapallo A, Geido E, Sciutto A, Merlo F, Risio M, Rossini FP.
(SEC
  (FRAG (NNP:[189..197] Giaretti) (NNP:[198..199] W) (,:[199..200] ,)
        (NNP:[201..208] Rapallo) (NNP:[209..210] A) (,:[210..211] ,)
        (NNP:[212..217] Geido) (NNP:[218..219] E) (,:[219..220] ,)
        (NNP:[221..228] Sciutto) (NNP:[229..230] A) (,:[230..231] ,)
        (NNP:[232..237] Merlo) (NNP:[238..239] F) (,:[239..240] ,)
        (DT:[241..246] Risio) (NNP:[247..249] M,) (NNP:[250..257] Rossini)
        (NNP:[258..260] FP) (.:[260..261] .)))

;section 3 Span:265..407
;Laboratory of Biophysics-Cytometry, National Institute for Cancer Research
;and  Treatment, Candiolo, Genoa, Italy. giaretti@hp380.ist.unige.it
(SEC
  (FRAG (NN:[265..275] Laboratory) (IN:[276..278] of)
        (NNP:[279..289] Biophysics) (HYPH:[289..290] -)
        (NNP:[290..299] Cytometry) (,:[299..300] ,) (NNP:[301..309] National)
        (NNP:[310..319] Institute) (IN:[320..323] for) (NNP:[324..330] Cancer)
        (NNP:[331..339] Research) (CC:[340..343] and) (NNP:[345..354] Treatment)
        (,:[354..355] ,) (NNP:[356..364] Candiolo) (,:[364..365] ,)
        (NNP:[366..371] Genoa) (,:[371..372] ,) (NNP:[373..378] Italy)
        (.:[378..379] .) ('':[380..398] giaretti@hp380.ist)
        (VBD:[398..404] .unige) (.:[404..407] .it)))

;sentence 4 Span:411..589
;Recent studies indicate that p21ras proteins mediate their multiple cell 
;functions through interactions with multiple effectors and that the number of
; new effectors is growing.
;[440..446]:gene-protein:"p21ras"
(SENT
  (S
    (NP-SBJ (JJ:[411..417] Recent) (NNS:[418..425] studies))
    (VP (VBP:[426..434] indicate)
      (SBAR
        (SBAR (IN:[435..439] that)
          (S
            (NP-SBJ (NN:[440..446] p21ras) (NNS:[447..455] proteins))
            (VP (VBP:[456..463] mediate)
              (NP (PRP$:[464..469] their) (JJ:[470..478] multiple)
                  (NN:[479..483] cell) (NNS:[485..494] functions))
              (PP (IN:[495..502] through)
                (NP
                  (NP (NNS:[503..515] interactions))
                  (PP (IN:[516..520] with)
                    (NP (JJ:[521..529] multiple) (NNS:[530..539] effectors))))))))
        (CC:[540..543] and)
        (SBAR (IN:[544..548] that)
          (S
            (NP-SBJ
              (NP (DT:[549..552] the) (NN:[553..559] number))
              (PP (IN:[560..562] of)
                (NP (JJ:[564..567] new) (NNS:[568..577] effectors))))
            (VP (VBZ:[578..580] is)
              (VP (VBG:[581..588] growing)))))))
    (.:[588..589] .)))

;sentence 5 Span:590..734
;We recently reported that K-ras2 mutations in human  colorectal adenomas were
;associated with chromosome instability and  proliferation changes.
;[616..622]:gene-rna:"K-ras2"
;[643..662]:malignancy:"colorectal adenomas"
(SENT
  (S
    (NP-SBJ (PRP:[590..592] We))
    (ADVP-TMP (RB:[593..601] recently))
    (VP (VBD:[602..610] reported)
      (SBAR (IN:[611..615] that)
        (S
          (NP-SBJ-1
            (NP (NN:[616..622] K-ras2) (NNS:[623..632] mutations))
            (PP-LOC (IN:[633..635] in)
              (NP (JJ:[636..641] human)
                 (JJ:[643..653] colorectal) (NNS:[654..662] adenomas))))
          (VP (VBD:[663..667] were)
            (VP (VBN:[668..678] associated)
              (NP-1 (-NONE-:[678..678] *))
              (PP-CLR (IN:[679..683] with)
                (NP
                  (NP (NN:[684..694] chromosome) (NN:[695..706] instability))
                  (CC:[707..710] and)
                  (NP (NN:[712..725] proliferation) (NNS:[726..733] changes)))))))))
    (.:[733..734] .)))

;sentence 6 Span:735..796
;In the present study, we extend these previous  observations.
(SENT
  (S
    (PP (IN:[735..737] In)
      (NP (DT:[738..741] the) (JJ:[742..749] present) (NN:[750..755] study)))
    (,:[755..756] ,)
    (NP-SBJ (PRP:[757..759] we))
    (VP (VBP:[760..766] extend)
      (NP (DT:[767..772] these) (JJ:[773..781] previous)
          (NNS:[783..795] observations)))
    (.:[795..796] .)))

;sentence 7 Span:797..889
;Hereditary and multiple (n > or = 5) adenomas and adenomas with  early cancer
;were excluded.
;[797..807]...[834..842]:malignancy:"Hereditary"..."adenomas"
;[812..842]:malignancy:"multiple (n > or = 5) adenomas"
;[847..874]:malignancy:"adenomas with  early cancer"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP (JJ:[797..807] Hereditary)
          (NML-1 (-NONE-:[807..807] *P*)))
        (CC:[808..811] and)
        (NP (JJ:[812..820] multiple)
          (PRN (-LRB-:[821..822] -LRB-)
            (S
              (NP-SBJ (NN:[822..823] n))
              (VP (SYM:[824..825] >) (CC:[826..828] or) (SYM:[829..830] =)
                (NP (CD:[831..832] 5))))
            (-RRB-:[832..833] -RRB-))
          (NML-1 (NNS:[834..842] adenomas))))
      (CC:[843..846] and)
      (NP
        (NP (NNS:[847..855] adenomas))
        (PP (IN:[856..860] with)
          (NP (JJ:[862..867] early) (NN:[868..874] cancer)))))
    (VP (VBD:[875..879] were)
      (VP (VBN:[880..888] excluded)
        (NP-2 (-NONE-:[888..888] *))))
    (.:[888..889] .)))

;sentence 8 Span:890..981
;Dysplasia was moderate in 91 cases and high in 25,  and the median adenoma
;size was 1.5 cm.
;[890..899]:malignancy:"Dysplasia"
;[957..964]:malignancy:"adenoma"
(SENT
  (S
    (S
      (NP-SBJ (NN:[890..899] Dysplasia))
      (VP (VBD:[900..903] was)
        (ADJP-PRD
          (ADJP (JJ:[904..912] moderate)
            (PP (IN:[913..915] in)
              (NP (CD:[916..918] 91) (NNS:[919..924] cases))))
          (CC:[925..928] and)
          (ADJP (JJ:[929..933] high)
            (PP (IN:[934..936] in)
              (NP (CD:[937..939] 25)))))))
    (,:[939..940] ,) (CC:[942..945] and)
    (S
      (NP-SBJ (DT:[946..949] the) (JJ:[950..956] median) (NN:[957..964] adenoma)
              (NN:[965..969] size))
      (VP (VBD:[970..973] was)
        (NP-PRD (CD:[974..977] 1.5) (NN:[978..980] cm))))
    (.:[980..981] .)))

;sentence 9 Span:982..1161
;K-ras2 spectrum analysis was done by  sequence-specific oligonucleotide
;hybridization using nuclear suspensions  provided by analysis and sorting of
;multiparameter flow cytometry.
;[982..988]:gene-rna:"K-ras2"
(SENT
  (S
    (NP-SBJ-1 (NN:[982..988] K-ras2) (NN:[989..997] spectrum)
              (NN:[998..1006] analysis))
    (VP (VBD:[1007..1010] was)
      (VP (VBN:[1011..1015] done)
        (NP-1 (-NONE-:[1015..1015] *))
        (PP (IN:[1016..1018] by)
          (NP
            (ADJP (NN:[1020..1028] sequence) (HYPH:[1028..1029] -)
                  (JJ:[1029..1037] specific))
            (NN:[1038..1053] oligonucleotide) (NN:[1054..1067] hybridization)))
        (S-ADV
          (NP-SBJ (-NONE-:[1067..1067] *))
          (VP (VBG:[1068..1073] using)
            (NP
              (NP (JJ:[1074..1081] nuclear) (NNS:[1082..1093] suspensions))
              (VP (VBN:[1095..1103] provided)
                (NP (-NONE-:[1103..1103] *))
                (PP (IN:[1104..1106] by)
                  (NP
                    (NP
                      (NP (NN:[1107..1115] analysis))
                      (CC:[1116..1119] and)
                      (NP (NN:[1120..1127] sorting)))
                    (PP (IN:[1128..1130] of)
                      (NP (JJ:[1131..1145] multiparameter)
                          (NN:[1146..1150] flow) (NN:[1151..1160] cytometry)))))))))))
    (.:[1160..1161] .)))

;sentence 10 Span:1162..1312
;In  particular, tissue inflammatory cells were separated for DNA diploid
;tumors,  whereas DNA aneuploid epithelial subclones were analyzed
;separately.
;[1223..1234]:variation-type:"DNA diploid"
;[1235..1241]:malignancy:"tumors"
;[1252..1265]:variation-type:"DNA aneuploid"
;[1266..1286]:malignancy:"epithelial subclones"
(SENT
  (S
    (PP (IN:[1162..1164] In)
      (ADJP (JJ:[1166..1176] particular)))
    (,:[1176..1177] ,)
    (NP-SBJ-2 (NN:[1178..1184] tissue) (JJ:[1185..1197] inflammatory)
              (NNS:[1198..1203] cells))
    (VP (VBD:[1204..1208] were)
      (VP (VBN:[1209..1218] separated)
        (NP-2 (-NONE-:[1218..1218] *))
        (PP (IN:[1219..1222] for)
          (NP
             (NN:[1223..1226] DNA) (JJ:[1227..1234] diploid)
            (NNS:[1235..1241] tumors)))
        (,:[1241..1242] ,)
        (SBAR-ADV (IN:[1244..1251] whereas)
          (S
            (NP-SBJ-1
               (NN:[1252..1255] DNA) (JJ:[1256..1265] aneuploid)
               (JJ:[1266..1276] epithelial) (NNS:[1277..1286] subclones))
            (VP (VBD:[1287..1291] were)
              (VP (VBN:[1292..1300] analyzed)
                (NP-1 (-NONE-:[1300..1300] *))
                (ADVP (RB:[1301..1311] separately))))))))
    (.:[1311..1312] .)))

;sentence 11 Span:1313..1394
;K-ras2  mutations and DNA aneuploidy were both detected in 29 of 116 (25%)
;cases.
;[1313..1319]:gene-rna:"K-ras2"
;[1335..1349]:variation-type:"DNA aneuploidy"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[1313..1319] K-ras2) (NNS:[1321..1330] mutations))
      (CC:[1331..1334] and)
      (NP (NN:[1335..1338] DNA) (NN:[1339..1349] aneuploidy)))
    (VP (VBD:[1350..1354] were)
      (ADVP (DT:[1355..1359] both))
      (VP (VBN:[1360..1368] detected)
        (NP-1 (-NONE-:[1368..1368] *))
        (PP (IN:[1369..1371] in)
          (NP
            (NP (CD:[1372..1374] 29))
            (PP (IN:[1375..1377] of)
              (NP (CD:[1378..1381] 116)
                (PRN (-LRB-:[1382..1383] -LRB-)
                  (NP (CD:[1383..1385] 25) (NN:[1385..1386] %))
                  (-RRB-:[1386..1387] -RRB-))
                (NNS:[1388..1393] cases)))))))
    (.:[1393..1394] .)))

;sentence 12 Span:1395..1472
;DNA  aneuploid index was in the near-diploid region in the majority of
;cases.
;[1427..1439]:variation-type:"near-diploid"
(SENT
  (S
    (NP-SBJ (NN:[1395..1398] DNA) (JJ:[1400..1409] aneuploid)
            (NN:[1410..1415] index))
    (VP (VBD:[1416..1419] was)
      (PP-PRD (IN:[1420..1422] in)
        (NP (DT:[1423..1426] the)
          (ADJP (JJ:[1427..1431] near) (HYPH:[1431..1432] -)
                (JJ:[1432..1439] diploid))
          (NN:[1440..1446] region)))
      (PP (IN:[1447..1449] in)
        (NP
          (NP (DT:[1450..1453] the) (NN:[1454..1462] majority))
          (PP (IN:[1463..1465] of)
            (NP (NNS:[1466..1471] cases))))))
    (.:[1471..1472] .)))

;sentence 13 Span:1473..1540
;DNA  aneuploidy was strongly associated with G-->C/T transversions.
;[1473..1488]:variation-type:"DNA  aneuploidy"
;[1518..1519]:variation-state-original:"G"
;[1522..1523]:variation-state-altered:"C"
;[1524..1525]:variation-state-altered:"T"
;[1526..1539]:variation-type:"transversions"
(SENT
  (S
    (NP-SBJ-1 (NN:[1473..1476] DNA) (NN:[1478..1488] aneuploidy))
    (VP (VBD:[1489..1492] was)
      (ADVP (RB:[1493..1501] strongly))
      (VP (VBN:[1502..1512] associated)
        (NP-1 (-NONE-:[1512..1512] *))
        (PP-CLR (IN:[1513..1517] with)
          (NP
            (NML
              (NML (NN:[1518..1519] G))
              (PP (SYM:[1519..1522] -->)
                (NP (NN:[1522..1523] C) (SYM:[1523..1524] /) (NN:[1524..1525] T))))
            (NNS:[1526..1539] transversions)))))
    (.:[1539..1540] .)))

;sentence 14 Span:1541..1621
;An association  was also found between low S-phase values and G-->A
;transitions.
;[1603..1604]:variation-state-original:"G"
;[1607..1608]:variation-state-altered:"A"
;[1609..1620]:variation-type:"transitions"
(SENT
  (S
    (NP-SBJ-1 (DT:[1541..1543] An) (NN:[1544..1555] association))
    (VP (VBD:[1557..1560] was)
      (ADVP (RB:[1561..1565] also))
      (VP (VBN:[1566..1571] found)
        (NP-1 (-NONE-:[1571..1571] *))
        (PP (IN:[1572..1579] between)
          (NP
            (NP (JJ:[1580..1583] low) (NN:[1584..1591] S-phase)
                (NNS:[1592..1598] values))
            (CC:[1599..1602] and)
            (NP
              (NML
                (NML (NN:[1603..1604] G))
                (PP (SYM:[1604..1607] -->)
                  (NP (NN:[1607..1608] A))))
              (NNS:[1609..1620] transitions))))))
    (.:[1620..1621] .)))

;sentence 15 Span:1622..1774
;These findings  were confirmed using multivariate logistic regression
;analysis to account for  the effects of size, dysplasia, site, type, age, and
;sex.
;[1738..1747]:malignancy:"dysplasia"
(SENT
  (S
    (NP-SBJ-1 (DT:[1622..1627] These) (NNS:[1628..1636] findings))
    (VP (VBD:[1638..1642] were)
      (VP (VBN:[1643..1652] confirmed)
        (NP-1 (-NONE-:[1652..1652] *))
        (S-MNR
          (NP-SBJ (-NONE-:[1652..1652] *))
          (VP (VBG:[1653..1658] using)
            (NP (JJ:[1659..1671] multivariate) (JJ:[1672..1680] logistic)
                (NN:[1681..1691] regression) (NN:[1692..1700] analysis))
            (S-ADV
              (NP-SBJ (-NONE-:[1700..1700] *))
              (VP (TO:[1701..1703] to)
                (VP (VB:[1704..1711] account)
                  (PP (IN:[1712..1715] for)
                    (NP
                      (NP (DT:[1717..1720] the) (NNS:[1721..1728] effects))
                      (PP (IN:[1729..1731] of)
                        (NP (NN:[1732..1736] size) (,:[1736..1737] ,)
                            (NN:[1738..1747] dysplasia) (,:[1747..1748] ,)
                            (NN:[1749..1753] site) (,:[1753..1754] ,)
                            (NN:[1755..1759] type) (,:[1759..1760] ,)
                            (NN:[1761..1764] age) (,:[1764..1765] ,)
                            (CC:[1766..1769] and) (NN:[1770..1773] sex))))))))))))
    (.:[1773..1774] .)))

;sentence 16 Span:1775..1997
;These data suggest  that specific K-ras2 mutations in a subgroup of human
;sporadic colorectal  adenomas play a role in chromosome instability and,
;contrary to expectations,  are associated with inhibition of proliferation.
;[1809..1815]:gene-rna:"K-ras2"
;[1849..1878]:malignancy:"sporadic colorectal  adenomas"
(SENT
  (S
    (NP-SBJ (DT:[1775..1780] These) (NNS:[1781..1785] data))
    (VP (VBP:[1786..1793] suggest)
      (SBAR (IN:[1795..1799] that)
        (S
          (NP-SBJ-1
            (NP (JJ:[1800..1808] specific) (NN:[1809..1815] K-ras2)
                (NNS:[1816..1825] mutations))
            (PP (IN:[1826..1828] in)
              (NP
                (NP (DT:[1829..1830] a) (NN:[1831..1839] subgroup))
                (PP (IN:[1840..1842] of)
                  (NP (JJ:[1843..1848] human)
                     (JJ:[1849..1857] sporadic) (JJ:[1858..1868] colorectal)
                     (NNS:[1870..1878] adenomas))))))
          (VP
            (VP (VBP:[1879..1883] play)
              (NP (DT:[1884..1885] a) (NN:[1886..1890] role))
              (PP (IN:[1891..1893] in)
                (NP (NN:[1894..1904] chromosome) (NN:[1905..1916] instability))))
            (CC:[1917..1920] and) (,:[1920..1921] ,)
            (S-ADV
              (NP-SBJ (-NONE-:[1921..1921] *))
              (ADJP-PRD (JJ:[1922..1930] contrary)
                (PP (TO:[1931..1933] to)
                  (NP (NNS:[1934..1946] expectations)))))
            (,:[1946..1947] ,)
            (VP (VBP:[1949..1952] are)
              (VP (VBN:[1953..1963] associated)
                (NP-1 (-NONE-:[1963..1963] *))
                (PP-CLR (IN:[1964..1968] with)
                  (NP
                    (NP (NN:[1969..1979] inhibition))
                    (PP (IN:[1980..1982] of)
                      (NP (NN:[1983..1996] proliferation)))))))))))
    (.:[1996..1997] .)))

;section 17 Span:2001..2045
;PMID: 9777951 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2001..2005] PMID) (::[2005..2006] :) (CD:[2007..2014] 9777951)
        (IN:[2015..2016] -LSB-) (NNP:[2016..2022] PubMed) (HYPH:[2023..2024] -)
        (JJ:[2025..2032] indexed) (IN:[2033..2036] for)
        (NNP:[2037..2045] MEDLINE-RSB-)))
